ProQR Therapeutics

ProQR Therapeutics Equity

The The Equity of ProQR Therapeutics (PRQR) as of Nov 16, 2026 is 57.99 M EUR. In the previous year, The Equity was 91.70 M EUR — a change of -36.77% (lower).

Equity

57.99 MEUR

YoY

-36.77%

Last updated:

In 2025, ProQR Therapeutics's equity was 57.99 M EUR, a -36.77% increase from the 91.70 M EUR equity in the previous year.

The ProQR Therapeutics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
92.69 M EUR
Jan 1, 2019
105.88 M EUR
Jan 1, 2020
69.85 M EUR
Jan 1, 2021
129.45 M EUR
Jan 1, 2022
71.58 M EUR
Jan 1, 2023
45.72 M EUR
Jan 1, 2024
91.70 M EUR
Jan 1, 2025
57.99 M EUR
The ProQR Therapeutics Equity history
YEAREquityYoY
57.99 MEUR-36.77%
91.70 MEUR+100.57%
45.72 MEUR-36.12%
71.58 MEUR-44.71%
129.45 MEUR+85.32%
69.85 MEUR-34.03%
105.88 MEUR+14.24%
92.69 MEUR+96.09%
47.27 MEUR-15.66%
56.05 MEUR-42.55%
97.55 MEUR-26.31%
132.38 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProQR Therapeutics Stock analysis

What does ProQR Therapeutics do? ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight. ProQR Therapeutics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing ProQR Therapeutics's Equity

ProQR Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ProQR Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ProQR Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ProQR Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ProQR Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ProQR Therapeutics stock

The Equity of ProQR Therapeutics is 57.99 M EUR in 2025.

The Equity of ProQR Therapeutics changed from 91.70 M EUR to 57.99 M EUR, representing a -36.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity ProQR Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's ProQR Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ProQR Therapeutics

All Key Metrics — ProQR Therapeutics